263 related articles for article (PubMed ID: 35550867)
1. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
Kobayashi M; Motoki Y; Yamagishi T; Hirano H; Nonaka M; Aono A; Mitarai S; Saito T
J Infect Chemother; 2022 Aug; 28(8):1193-1197. PubMed ID: 35550867
[TBL] [Abstract][Full Text] [Related]
2. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
[TBL] [Abstract][Full Text] [Related]
3. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
4. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
5. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
7. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.
Le Ray LF; Aubry A; Sougakoff W; Revest M; Robert J; Bonnet I; Veziris N; Morel F
Emerg Infect Dis; 2022 May; 28(5):1062-1064. PubMed ID: 35447056
[TBL] [Abstract][Full Text] [Related]
8. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
12. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
[TBL] [Abstract][Full Text] [Related]
13. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
[TBL] [Abstract][Full Text] [Related]
14. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
15. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
[TBL] [Abstract][Full Text] [Related]
16. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
[TBL] [Abstract][Full Text] [Related]
17. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
[No Abstract] [Full Text] [Related]
19. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
[TBL] [Abstract][Full Text] [Related]
20. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]